First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Chronic lymphocytic leukemia (CLL) predominantly affects elderly individuals, yet most clinical trials exclude this demographic.
• Limited treatment options exist for elderly and medically less fit CLL patients.

Purpose of the Study:

• To evaluate the impact of comorbidities on outcomes in elderly CLL patients.
• To compare the efficacy of three distinct immunochemotherapy regimens in this population.

Main Methods:

• Retrospective analysis of 143 CLL patients aged over 65 years.
• Treatment regimens included fludarabine, cyclophosphamide, and rituximab (FCR), fludarabine and rituximab (FR), or rituximab with chlorambucil (R-CLB).

Main Results:

• FCR demonstrated higher clinical response rates (75%) compared to FR (57%) and R-CLB (28%).
• Two-year progression-free survival (PFS) was significantly better with FCR (90%) and FR (58%) versus R-CLB (30%).
• Higher rituximab doses (500mg/m²) correlated with prolonged PFS in fludarabine-based regimens.

Conclusions:

• Elderly CLL patients derive significant benefit from frontline immunochemotherapy.
• Maintaining rituximab dose intensity is crucial for optimizing outcomes in this patient group.